Work With Us
Contact Us
Work With Us
Contact Us
Search
Home
About Us
Our Mission and Vision
Meet the Team
Board of Directors
Scientific Advisory Board
Investors
Our Science
About Macrocycles
Introducing MXMO
TM
Our Pipeline
Clinical Trials
Publications
What’s New
Press Releases
Events
Home
About Us
Our Mission and Vision
Meet the Team
Board of Directors
Scientific Advisory Board
Investors
Our Science
About Macrocycles
Introducing MXMO
TM
Our Pipeline
Clinical Trials
Publications
What’s New
Press Releases
Events
Publications
Publications
CID-078, a first-in-class oral cyclin A/B-RxL inhibitor, elicits anti-tumor activity in breast cancer patient-derived xenograft models
December 9, 2024
Click here
Publications
CID-078, a First-in-Class Oral Macrocycle CyclinA/B-RxL Inhibitor, Demonstrates Anti-Tumor Activity in E2F-driven Cancers
October 23, 2024
Click here
Publications
Orally bioavailable Cyclin A/B RxL macrocycle has antitumor effect in SCLC and NSCLC cell line derived (CDX) and patient derived xenograft (PDX) models
September 9, 2024
Click here
Publications
Permeable macrocyclic peptide Cyclin A/B RxL inhibitors: synthetic development, SAR and in vivo target validation
August 22, 2024
Click here
Publications
Expanding Circle Pharma’s Discovery Synthesis Toolbox for Permeable Macrocycles With Automatable Bioisoteric Cyclization Chemistries
August 12, 2024
Click here
Publications
Application of a Semi-Automated Solid-Phase Synthesis Platform for the Discovery of Macrocyclic Peptide Cyclin A RxL Inhibitors
August 12, 2024
Click here
LOAD MORE
Sign up to stay informed
SUBSCRIBE
Subscribe to our News Alerts
By checking the box and pressing the subscribe button , I acknowledge and accept Circle Pharma’s
Privacy Policy
and
Terms of Service.
Subscribe
